- 0
- 583 words
The Special Investment Facilitation Council (SIFC) has convened a detailed meeting to review progress on key reforms in Pakistan’s health and pharmaceutical sectors. The session reviewed strategic reforms, investment facilitation measures and development initiatives aimed at strengthening healthcare infrastructure, boosting local pharmaceutical manufacturing and attracting domestic and foreign investment.
According to the review, the SIFC health and pharmaceutical reforms focus on regulatory streamlining, research and development, the availability of affordable medicines and positioning Pakistan as a regional hub for pharmaceutical production.
FAKTA
- The meeting: the SIFC reviewed progress on health and pharmaceutical sector reforms and key development initiatives.
- Health focus: healthcare infrastructure, service delivery, primary care and preventive medicine.
- Pharma focus: local manufacturing capacity, research and development, and affordable, quality medicines.
- Investment goal: streamlined regulation, fiscal incentives and foreign direct investment in both sectors.
Strategic reforms in the health sector
The meeting reviewed strategic reforms across Pakistan’s health sector aimed at strengthening healthcare infrastructure, improving service delivery and widening access for citizens, with particular emphasis on primary healthcare and preventive medicine.
Priorities include reducing the burden of communicable and non-communicable diseases, expanding telemedicine and digital health adoption, and extending equitable care to remote and underserved regions.
Pharmaceutical industry development
Significant attention was given to developing the pharmaceutical industry — boosting local manufacturing capacity, enhancing research and development, and ensuring the availability of affordable, high-quality medicines. The council aims to position Pakistan as a regional hub for pharmaceutical production.

The SIFC has been engaging industry stakeholders, including the Pakistan Pharmaceutical Manufacturers Association (PPMA), on regulatory reforms. The News reported that industry leaders credited drug deregulation with improving medicine availability and lifting pharmaceutical exports, while urging the council to safeguard the reform policy.
Investment facilitation measures
As a facilitator for investment, the council discussed measures to streamline regulatory processes, offer incentives and create a conducive environment for domestic and foreign investors in the health and pharmaceutical sectors.
Strategies for attracting foreign direct investment include promoting Pakistan’s market potential and skilled workforce, facilitating joint ventures and technology-transfer agreements. More coverage: Pakistan news on Watan News.
Challenges and outlook
The meeting also acknowledged persistent challenges: supply-chain vulnerabilities in medicine distribution, the need for a stronger pipeline of skilled health professionals, equitable access across diverse regions and keeping pace with evolving global health standards and technology.
The council committed to addressing these hurdles through targeted interventions and policy adjustments.
Conclusion
The SIFC session signals a determined push to revitalise Pakistan’s health and pharmaceutical sectors. If the reform and investment agenda translates into delivery, the payoff would be a stronger healthcare system and a more competitive domestic pharmaceutical industry.
Frequently Asked Questions
What is the Special Investment Facilitation Council (SIFC)?
The SIFC is a high-level Pakistani body that facilitates and accelerates investment in priority sectors of the economy.
Which sectors did the meeting cover?
The meeting focused on reforms and development initiatives in Pakistan’s health and pharmaceutical sectors.
What are the main goals of the reforms?
Better healthcare services, stronger local pharmaceutical manufacturing, affordable medicines and greater domestic and foreign investment.
How does the SIFC plan to attract investment?
Through streamlined regulations, fiscal incentives, joint ventures and promotion of Pakistan’s market potential to foreign investors.
What challenges were noted?
Supply-chain gaps in medicine distribution, workforce development, equitable access in remote areas and adapting to global health standards.